DARE-APS, a new clinical trial investigating the safety of the drug Darzalex® (daratumumab) in patients with antiphospholipid syndrome (APS) is now open for enrollment at two study sites.
DARE-APS: a new clinical trial
read more
Seeking Participants: Pregnancy and Antiphospholipid Syndrome (APS) Study
We are looking for people who have primary APS, are 18-45 years old, and have been or are considering becoming pregnant. You are eligible if you have ever been pregnant.
COVID19
The COVID-19 (Novel coronavirus) pandemic has quickly infected over a million people worldwide. At this time, little is known about how patients with rheumatic diseases, many of whom use medications and drugs that suppress the immune system, are affected by the virus. Here is a study for adults with rheumatic diseases, and parents of children with rheumatic diseases. Click the button to learn more about eligibility and participate in the survey.
If You Have Antiphospholipid Syndrome (APS) And Lupus, You May Qualify For A Research Study
The Paisley Study is a research study that is evaluating an oral investigational drug for people with moderate to severe systemic lupus erythematosus (SLE)…
Rare Diseases Clinical Research Network
The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease...
Clinical Study: PROMISSE
NOW RECRUITING Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE) The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study...
Clinical Study: Genetic Risk Factors Associated With APS
NOW RECRUITING Genetic Risk Factors Associated With Antiphospholipid Syndrome (APS) Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies, which are proteins in the blood that interfere with the body's ability to perform...
APS ACTION
The primary mission of APS ACTION is to prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research. Their secondary mission is to refine and advance the...
Recent Posts
Fall/Winter Antiphospho…what?! Newsletter
The Fall/Winter 2024 volume of our newsletter, "Antiphospho...What??" is ready …Read More »The APSFA Giving Tree is back!
It's that time of year again. The annual APSFA Giving …Read More »DARE-APS: a new clinical trial
DARE-APS, a new clinical trial investigating the safety of the …Read More »Seeking Participants: Pregnancy and Antiphospholipid Syndrome (APS) Study
We are looking for people who have primary APS, are …Read More »Donate to the APSFA
Founded in 2005, the APS Foundation of America, Inc. (APSFA) …Read More »
Our Mission
Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.